We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
- Authors
Cortellini, Alessio; Vitale, Maria G.; De Galitiis, Federica; Di Pietro, Francesca R.; Berardi, Rossana; Torniai, Mariangela; De Tursi, Michele; Grassadonia, Antonino; Di Marino, Pietro; Santini, Daniele; Zeppola, Tea; Anesi, Cecilia; Gelibter, Alain; Occhipinti, Mario Alberto; Botticelli, Andrea; Marchetti, Paolo; Rastelli, Francesca; Pergolesi, Federica; Tudini, Marianna; Silva, Rosa Rita
- Abstract
<bold>Background: </bold>Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial.<bold>Methods: </bold>The aim of this retrospective multicenter study was to evaluate the correlations between "early ir-fatigue", "delayed ir-fatigue", and clinical outcomes in cancer patients receiving PD-1/PD-L1 inhibitors in clinical practice.<bold>Results: </bold>517 patients were evaluated. After the 12-weeks landmark selection, 386 (74.7%) patients were eligible for the clinical outcomes analysis. 40.4% were NSCLC, 42.2% were melanoma, 15.3% renal cell carcinoma and 2.1% other malignancies. 76 patients (19.7%) experienced early ir-fatigue (within 1 month from treatment commencement), while 150 patients (38.9%) experienced delayed ir-fatigue. Early ir-fatigue was significantly related to shortened PFS (HR = 2.29 [95% CI 1.62-3.22], p < 0.0001) and OS (HR = 2.32 [95% CI 1.59-3.38], p < 0.0001) at the multivariate analysis. On the other hand, we found a significant association between the occurrence of early ir-fatigue, ECOG-PS ≥ 2 (p < 0.0001), and disease burden (p = 0.0003). Delayed ir-fatigue was not significantly related to PFS nor OS.<bold>Conclusions: </bold>Early ir-fatigue seems to be negative prognostic parameter, but to proper weight its role we must to consider the predominant role of performance status, which was related to early ir-fatigue in the study population.
- Subjects
FATIGUE (Physiology); PROGRAMMED cell death 1 receptors; CANCER fatigue; CANCER patients; RENAL cell carcinoma; ADVERSE health care events; MULTIVARIATE analysis
- Publication
Journal of Translational Medicine, 2019, Vol 17, Issue 1, pN.PAG
- ISSN
1479-5876
- Publication type
journal article
- DOI
10.1186/s12967-019-02132-x